Upon immune checkpoint blockade, TMP195 combined with an anti-programmed cell death-1 (PD-1) regimen could significantly reduce the tumor volume and induce a durable response in breast cancer (Guerriero et al., 2017). This evidence concerns the gene PDCD1 and breast carcinoma.